Abstract 3285
Background
The occurrence of colorectal cancer in individuals with potentially reproductive age has increased. Oxaliplatin is a cornerstone treatment in the adjuvant setting for stage III and high-risk stage II colorectal cancer in patients up to 70 years of age. The aim of this study was to investigate sex hormones and sperm function after oxaliplatin-based chemotherapy to clarify the risk for hypogonadism and infertility.
Methods
Through 2006-2013 20 males (aged ≤55 and younger) and 16 females (aged ≤40 and younger) were included. All had undergone radical surgery due to colorectal cancer, and were planned for adjuvant oxaliplatin in combination with 5-fluorouracil. Measurement of LH, FSH, testosterone, SHBG and sperm analysis was done in males. LH, FSH and estradiol was measured in females. Measurements were done after surgery, after cessation of adjuvant cytostatic treatment and at follow-up 1-5 years after end of treatment.
Results
FSH and testosterone levels increased in males, but were restored at follow-up. No patients went from normal gonadal function to hypogonadism. There was a tendency towards a decrease in sperm concentration, (p = 0.,063). When comparing sperm concentration and rapid progressive motility before treatment and at follow-up, there was no differences, and we observed no patients that turned overtly infertile by treatment. No distinct altering of gonadal function could be observed in the females.
Conclusions
From the results of this study, oxaliplatin seems to incur transient decrease in sperm concentration with recovery, and some but not pronounced increase in FSH in males. The risk for infertility and hypogonadism in males and females after adjuvant oxaliplatin-based chemotherapy seems to be low to moderate, but the general recommendation of appropriate fertility conserving measures shall should not be changed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Österlund: Honoraria (self): Amgen; Honoraria (self): Bayer; Honoraria (self): Celgene; Honoraria (self): Eli Lilly; Honoraria (self): Merck; Honoraria (self): Nordic Drugs; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Servier; Travel / Accommodation / Expenses: Pierre Fabre; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: AbbVie. E. Hofsli: Honoraria (self): Amgen. H. Sorbye: Honoraria (self): Novartis; Honoraria (self): Ipsen; Honoraria (self): Pfizer; Honoraria (self): Keocyt; Honoraria (self): AstraZeneca; Honoraria (self): Roche; Honoraria (self): Amgen; Honoraria (self): Merck; Honoraria (self): Shire; Honoraria (self): Celgene; Honoraria (self): Nordic Drugs. All other authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract